{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:13Z","timestamp":1787019613551,"version":"build-2736575974"},"reference-count":33,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2023,7,3]]},"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1183\/13993003.01008-2023","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T04:45:43Z","timestamp":1691037943000},"page":"2301008","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Long-term therapy with elexacaftor\/tezacaftor\/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist"],"prefix":"10.1183","volume":"62","author":[{"given":"Michael M.","family":"Tunney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"2024102012325035000_62.2.2301008.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.58.071905.105316"},{"key":"2024102012325035000_62.2.2301008.2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0042-1758732","article-title":"Microbial epidemiology of the cystic fibrosis airways: past, present, and future","volume":"44","author":"Thornton","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102012325035000_62.2.2301008.3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"2024102012325035000_62.2.2301008.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024102012325035000_62.2.2301008.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024102012325035000_62.2.2301008.6","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ppul.26485","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on lung disease in cystic fibrosis","volume":"58","author":"Gushue","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024102012325035000_62.2.2301008.7","doi-asserted-by":"crossref","first-page":"1176815","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024102012325035000_62.2.2301008.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.01.007"},{"key":"2024102012325035000_62.2.2301008.9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2024102012325035000_62.2.2301008.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200708-1151OC"},{"key":"2024102012325035000_62.2.2301008.11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jcf.2019.02.012","article-title":"Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis","volume":"18","author":"Sherrard","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024102012325035000_62.2.2301008.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00242-2018"},{"key":"2024102012325035000_62.2.2301008.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126980"},{"key":"2024102012325035000_62.2.2301008.14","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-020-00810-3"},{"key":"2024102012325035000_62.2.2301008.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00832-2017"},{"key":"2024102012325035000_62.2.2301008.16","doi-asserted-by":"crossref","first-page":"764585","DOI":"10.3389\/fcimb.2021.764585","article-title":"Microbial community composition in explanted cystic fibrosis and control donor lungs","volume":"11","author":"Einarsson","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024102012325035000_62.2.2301008.17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120577109"},{"key":"2024102012325035000_62.2.2301008.18","doi-asserted-by":"publisher","DOI":"10.1038\/srep10241"},{"key":"2024102012325035000_62.2.2301008.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.12.023"},{"key":"2024102012325035000_62.2.2301008.20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu944"},{"key":"2024102012325035000_62.2.2301008.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024102012325035000_62.2.2301008.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2024102012325035000_62.2.2301008.23","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219943"},{"key":"2024102012325035000_62.2.2301008.24","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","article-title":"A restructuring of microbiome niche space is associated with elexacaftor-tezacaftor-ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski LM","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102012325035000_62.2.2301008.25","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2024102012325035000_62.2.2301008.26","doi-asserted-by":"crossref","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"2024102012325035000_62.2.2301008.27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024102012325035000_62.2.2301008.28","doi-asserted-by":"crossref","unstructured":"Wiesel V , Aviram M , Mei-Zahav M , et al. Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study. J Cyst Fibros 2023; in press [https:\/\/doi.org\/10.1016\/j.jcf.2023.05.003].","DOI":"10.1183\/13993003.congress-2023.OA1542"},{"key":"2024102012325035000_62.2.2301008.29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024102012325035000_62.2.2301008.30","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201407-310OC"},{"key":"2024102012325035000_62.2.2301008.31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3310\/nihropenres.13260.1","article-title":"Exploring the nature of perceived treatment burden: a study to compare treatment burden measures in adults with cystic fibrosis","volume":"2","author":"Altabee","year":"2022","journal-title":"NIHR Open Res"},{"key":"2024102012325035000_62.2.2301008.32","doi-asserted-by":"crossref","unstructured":"Guenther EL , McCoy KS , Eisner M , et al. Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: a retrospective review. J Cyst Fibros 2023; in press [https:\/\/doi.org\/10.1016\/j.jcf.2023.03.018].","DOI":"10.1016\/j.jcf.2023.03.018"},{"key":"2024102012325035000_62.2.2301008.33","doi-asserted-by":"crossref","unstructured":"Manika K , Diamantea F , Tsakona A , et al. Use of cystic fibrosis inhaled medication before and after elexacaftor\/tezacaftor\/ivacaftor initiation. J Cyst Fibros 2023; in press [https:\/\/doi.org\/10.1016\/j.jcf.2023.05.001].","DOI":"10.1016\/j.jcf.2023.05.001"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01008-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:15:08Z","timestamp":1740363308000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01008-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,8,3]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1183\/13993003.01008-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01008-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}